Clinical Trials List
2024-10-01 - 2035-12-31
Phase II
Not yet recruiting1
Recruiting2
ICD-10C68.0
Malignant neoplasm of urethra
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9189.3
Malignant neoplasm of urethra
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Tai-Jan Chiu Division of Hematology & Oncology
- 陳彥達 Division of Urology
- 吳佳哲 Division of Hematology & Oncology
- 郭明濬 Division of Hematology & Oncology
- 黃詩喻 Division of Hematology & Oncology
- 林昶廷 Division of Hematology & Oncology
- 陳建旭 Division of Urology
- 羅浩倫 Division of Urology
- 常景棣 Division of Radiology
- 陳彥豪 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- PO-MING CHOW Division of Urology
- - - Division of Urology
- YU-CHUAN LU Division of Hematology & Oncology
- CHUNG-HSIN CHEN Division of Urology
- FU-JEN HSUEH Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- - - Division of Urology
- 闕士傑 Division of Urology
- 吳書丞 Division of Hematology & Oncology
- JIAN-HUA HONG Division of Urology
- Yeong-Shiau Pu Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳威任 Division of Urology
- I-Shen Huang Division of Urology
- Hsiao-Jen Chung Division of Urology
- Yen-Hwa Chang Division of Urology
- 蔡承翰 Division of Urology
- Tzu-chun Wei Division of Urology
- Mu-Hsin Chang Division of Hematology & Oncology
- William Huang Division of Urology
- Jiun-I Lai Division of Hematology & Oncology
- Tzu-Ping Lin Division of Urology
- Jia-An Hong Division of Radiology
- 彭昱璟 Division of Others
- Yi-Hsiu Huang Division of Urology
- Chueh-Chuan Yen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
350 participants